Vaxart, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 05, 2021 at 04:23 pm EDT
Share
Vaxart, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 112,000 compared to USD 523,000 a year ago. Operating loss was USD 15.775 million compared to USD 8.526 million a year ago. Net loss was USD 16.116 million compared to USD 8.977 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.12 a year ago. For the half year, total revenue was USD 618,000 compared to USD 3.425 million a year ago. Operating loss was USD 31.286 million compared to USD 9.220 million a year ago. Net loss was USD 32.123 million compared to USD 10.274 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.15 a year ago.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
VAXART, INC. 
